Follow Us
© 2026 Arizent. All rights reserved.
IMGCAP(1)]
NEW YORK | Thu Mar 10, 2011 7:05pm EST – Blood pressure drugs known as beta-blockers could be helping to fuel the obesity epidemic, by dampening the body’s ability to burn calories and fat over the long term, researchers say in a new report.
For reprint and licensing requests for this article, click here.
As healthcare expenses approach double-digit increases, employers are looking for savings in waste, care delivery, and plan administration before cutting benefits.
Employers face another steep rise in healthcare expenses in 2027, prompting a closer look at GLP-1 coverage, pharmacy spending and high-cost conditions.
The structure of a workweek, and employees' daily schedules, can have a significant impact on their nutrition and overall health.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
As more Americans turn to GLP-1 medications for weight loss, employers are weighing the benefits of coverage against rising healthcare expenses and long-term costs.
